<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="brief-report" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">719705</article-id>
<article-id pub-id-type="doi">10.3389/fcell.2021.719705</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells</article-title>
<alt-title alt-title-type="left-running-head">Wang et al.</alt-title>
<alt-title alt-title-type="right-running-head">CRISPR-Cas12a Recombination in Human Cells</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Chengkun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1360037/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xia</surname>
<given-names>Qiong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1360028/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Qianhe</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qu</surname>
<given-names>Yuanhao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1375641/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Su</surname>
<given-names>Stephen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cheng</surname>
<given-names>Jason K. W.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1436702/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hughes</surname>
<given-names>Nicholas W.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1360026/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cong</surname>
<given-names>Le</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1044763/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Pathology, Stanford University School of Medicine</institution>, <addr-line>Stanford</addr-line>, <addr-line>CA</addr-line>, <country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Genetics, Stanford University School of Medicine</institution>, <addr-line>Stanford</addr-line>, <addr-line>CA</addr-line>, <country>United States</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Wu Tsai Neuroscience Institute, Stanford University</institution>, <addr-line>Stanford</addr-line>, <addr-line>CA</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1044393/overview">Dali Li</ext-link>, East China Normal University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1245155/overview">Ivanka Markovic</ext-link>, University of Belgrade, Serbia</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/938256/overview">Huiming Lu</ext-link>, University of Texas Southwestern Medical Center, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Le Cong, <email>congle@stanford.edu</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Cellular Biochemistry, a section of the journal Frontiers in Cell and Developmental Biology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>9</volume>
<elocation-id>719705</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>06</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Wang, Xia, Zhang, Qu, Su, Cheng, Hughes and Cong.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Wang, Xia, Zhang, Qu, Su, Cheng, Hughes and Cong</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The development of CRISPR-based gene-editing technologies has brought an unprecedented revolution in the field of genome engineering. Cas12a, a member of the Class 2 Type V CRISPR-associated endonuclease family distinct from Cas9, has been repurposed and developed into versatile gene-editing tools with distinct PAM recognition sites and multiplexed gene targeting capability. However, with current CRISPR/Cas12a technologies, it remains a challenge to perform efficient and precise genome editing of long sequences in mammalian cells. To address this limitation, we utilized phage recombination enzymes and developed an efficient CRISPR/Cas12a tool for multiplexed precision editing in mammalian cells. Through protein engineering, we were able to recruit phage recombination proteins to Cas12a to enhance its homology-directed repair efficiencies. Our phage-recombination-assisted Cas12a system achieved up to 3-fold improvements for kilobase-scale knock-ins in human cells without compromising the specificity of the enzyme. The performance of this system compares favorably against Cas9 references, the commonly used enzyme for gene-editing tasks, with improved specificity. Additionally, we demonstrated multi-target editing with similar improved activities thanks to the RNA-processing activity of the Cas12a system. This compact, multi-target editing tool has the potential to assist in understanding multi-gene interactions. In particular, it paves the way for a gene therapy method for human diseases that complements existing tools and is suitable for polygenic disorders and diseases requiring long-sequence corrections.</p>
</abstract>
<kwd-group>
<kwd>CRISPR</kwd>
<kwd>genome editing</kwd>
<kwd>Cas12a</kwd>
<kwd>RecT</kwd>
<kwd>single-stranded annealing protein</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Human Genome Research Institute<named-content content-type="fundref-id">10.13039/100000051</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Donald E. and Delia B. Baxter Foundation<named-content content-type="fundref-id">10.13039/100007491</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The powerful CRISPR technologies have been widely applied in various biological systems and are greatly changing the field of genome engineering (<xref ref-type="bibr" rid="B4">Cong et al., 2013</xref>; <xref ref-type="bibr" rid="B7">Jinek et al., 2013</xref>; <xref ref-type="bibr" rid="B5">Hsu et al., 2014</xref>; <xref ref-type="bibr" rid="B12">Komor et al., 2017</xref>; <xref ref-type="bibr" rid="B11">Knott and Doudna, 2018</xref>). Cas12a(Cpf1), a member of the Class 2 Type V CRISPR-associated endonuclease family, differs from Cas9 in several ways (<xref ref-type="bibr" rid="B24">Zetsche et al., 2015</xref>): it has a T-rich PAM recognition site (TTTV) while Cas9 PAM site is G-rich (NGG) (<xref ref-type="bibr" rid="B24">Zetsche et al., 2015</xref>; <xref ref-type="bibr" rid="B23">Yamano et al., 2016</xref>); its guide RNA is shorter in sequence than Cas9 (<xref ref-type="bibr" rid="B24">Zetsche et al., 2015</xref>); Cas12a cuts DNA distal and downstream relative to the PAM sequence and results in staggered ends while Cas9 cuts DNA proximal and upstream and results in blunt ends; and Cas12a is reported to be more precise and induces less off-target activities than Cas9 (<xref ref-type="bibr" rid="B24">Zetsche et al., 2015</xref>; <xref ref-type="bibr" rid="B8">Kim et al., 2016</xref>; <xref ref-type="bibr" rid="B10">Kleinstiver et al., 2016</xref>; <xref ref-type="bibr" rid="B23">Yamano et al., 2016</xref>; <xref ref-type="bibr" rid="B18">Swarts et al., 2017</xref>). Moreover, due to its intrinsic ribonuclease activity that processes its own crRNA, Cas12a is capable of multiplex editing from a single RNA transcript (<xref ref-type="bibr" rid="B24">Zetsche et al., 2015</xref>; <xref ref-type="bibr" rid="B25">Zetsche et al., 2017</xref>).</p>
<p>Multiplex engineering can be useful in understanding gene-gene interactions, combinatorial effects of different genetic mutations, and biological pathways with redundancy between individual genes (<xref ref-type="bibr" rid="B19">Tak et al., 2017</xref>; <xref ref-type="bibr" rid="B13">Li et al., 2019</xref>; <xref ref-type="bibr" rid="B16">McCarty et al., 2020</xref>). Along with its other beneficial properties, Cas12a holds great potential in serving as a tool to solve genome engineering problems. However, similar to Cas9, Cas12a relies on endogenous homology-directed repair (HDR) mechanisms to achieve precise gene modifications, but the HDR efficiency is often very limited due to the competing error-prone repair pathways which happen much more frequently (<xref ref-type="bibr" rid="B17">Pickar-Oliver and Gersbach, 2019</xref>; <xref ref-type="bibr" rid="B1">Anzalone et al., 2020</xref>). While many previous studies have been done to improve the efficiency of base editing and short genomic alterations, large-scale genome editing using Cas12a still remains a challenge (<xref ref-type="bibr" rid="B14">Li et al., 2018</xref>; <xref ref-type="bibr" rid="B9">Kleinstiver et al., 2019</xref>; <xref ref-type="bibr" rid="B22">Wang et al., 2020</xref>).</p>
<p>Previously we have identified that phage single-stranded annealing proteins (SSAPs) could enhance Cas9-based gene editing efficiencies in mammalian cells, and among all SSAPs screened, <italic>E. coli</italic> RecT exhibited the largest increase (<xref ref-type="bibr" rid="B21">Wang et al., 2021</xref>). We termed this high-efficiency Cas9 editing method as RecT Editor <italic>via</italic> Designer-Cas9-Initiated Targeting (REDIT). Here, combining the efficiency of REDIT and the multi-target editing ability of Cas12a, we developed a new Cas12a-REDIT method.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Plasmids Construction</title>
<p>The fragment encoding the scFV-RecT or GFP was Gibson assembled into MS2-P65-HSF1-GFP (addgene, 61423) using NEBuilder HiFi DNA Assembly Master Mix (New England BioLabs), the MS2-P65-HSF1-GFP plasmid digested with BsiWI and EcoRI. The fragment encoding Cas12a-10x GCN4 was Gibson assembled into the pX330 (42230; addgene), pX330 was digested with AgeI and EcoRI. The guide RNAs were then inserted using Golden Gate cloning (guideRNA sequence used in this study could be find in the <xref ref-type="sec" rid="s9">Supplementary Table</xref>). All plasmids were sequence-verified (Eton and Genewiz) through Sanger sequencing and will be deposited to Addgene for open access.</p>
</sec>
<sec id="s2-2">
<title>Cell Culture</title>
<p>Human Embryonic Kidney (HEK) 293T cells was ordered from ThermoFisher; Hela and HepG2 were obtained from American Type Culture Collection (ATCC). All three cell lines were maintained in Dulbecco&#x2019;s Modified Eagle&#x2019;s Medium (DMEM, Life Technologies), with 10% fetal bovine serum (FBS, BenchMark), 100 U/ml penicillin, and 100&#xa0;&#x3bc;g/ml streptomycin (Life Technologies) at 37&#xb0;C with 5% CO<sub>2</sub>.</p>
</sec>
<sec id="s2-3">
<title>Transfection</title>
<p>HEK293T cells were seeded into 96-well plates (Corning) 12&#xa0;h prior to transfection at a density of 3E4 cells/well, and 250&#xa0;ng of total DNA was transfected per well using Lipofectamine 3000 (Life Technologies) following the manufacturer&#x2019;s instruction. HeLa and HepG2 cells were seeded into 48-well plates (Corning) 1&#xa0;day prior to transfection at a density of 5E4 and 3E4 cells/well respectively, and 400&#xa0;ng of total DNA was transfected per well.</p>
</sec>
<sec id="s2-4">
<title>Fluorescence-Activated Cell Sorting (FACS)</title>
<p>72&#xa0;h after transfection, cells were washed with PBS and dissociated using 50&#xa0;&#x3bc;l TrypLE Express Enzyme (Thermo Fisher Scientific). Cell suspension was then transferred to a 96-well U-bottom plate (Thermo Fisher Scientific) and centrifuged at 300&#xa0;g for 5&#xa0;min. After removing the supernatant, pelleted cells were resuspended with 50&#xa0;&#x3bc;l 4% FBS in PBS, and the mKate or GFP knock-in efficiency was analyzed on a CytoFLEX flow cytometer (Beckman Coulter; Stanford Stem Cell FACS Core) within 30&#xa0;min.</p>
</sec>
<sec id="s2-5">
<title>Next-Generation Sequencing (NGS) Library Preparation</title>
<p>48&#x2013;72&#xa0;h after transfection, genomic DNA (gDNA) was extracted using QuickExtract DNA Extraction Solution (Lucigen). 200&#xa0;ng total gDNA was used for NGS library preparation. Genes of interest were amplified using specific primers (<xref ref-type="sec" rid="s9">Supplementary Table</xref>) for the first round of PCR reaction, and Illumina adapters and index barcodes were added in the second round of PCR. Final PCR products were run on a 2% E-gel (Thermo Fisher Scientific) and extracted using the Monarch DNA Gel Extraction Kit (New England BioLab). The purified product was quantified with Qubit dsDNA HS Assay Kit (Thermo Fisher) and loaded for sequencing using Illumina MiSeq paired-end PE300 kits following the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="s2-6">
<title>High-Throughput Sequencing Data Analysis</title>
<p>The sequencing data was analyzed using CRISPResso2 as previously described (<xref ref-type="bibr" rid="B3">Clement et al., 2019</xref>; <xref ref-type="bibr" rid="B21">Wang et al., 2021</xref>). Briefly, the sequencing reads were demultiplexed, trimmed and merged, then aligned to reference or expected HDR amplicons. Only reads perfectly matched to th expected amplicon were considered for HDR quantification. The computation work was supported by the SCG cluster hosted by the Genetics Bioinformatics Service Center (GBSC) at the Department of Genetics of Stanford. All sequencing data have been deposited by the authors into NCBI SRA archive, and could be identified by the accession ID PRJNA735023.</p>
</sec>
<sec id="s2-7">
<title>Statistical Analysis</title>
<p>Unless otherwise stated, all statistical analysis and comparison were performed using <italic>t</italic>-test, with 1% false-discovery-rate (FDR) using a two-stage step-up method of Benjamini, Krieger and Yekutieli. All experiments were performed in triplicates unless otherwise noted to ensure sufficient statistical power in the analysis.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and Discussion</title>
<p>We fused RecT to Cas12a <italic>via</italic> the previously reported SunTag-based recruitment system (<xref ref-type="bibr" rid="B20">Tanenbaum et al., 2014</xref>; <xref ref-type="bibr" rid="B6">Huang et al., 2017</xref>). In our design, Cas12a linking a tandem repeat of 10 copies of GCN4 peptides were cloned into a mammalian expression vector. The RecT protein (GFP protein in control) linking a single chain variable fragment (ScFv) of the anti-GCN4 antibody, was cloned into another vector. Upon the co-expression of two plasmids, ScFv antibodies would bind to their cognate peptide pair GCN4, recruiting RecT to the Cas12a protein (<xref ref-type="fig" rid="F1">Figure 1A</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Testing Cas12a-REDIT for genome engineering in mammalian cells. <bold>(A)</bold> Vector designs on the top and schematic on the bottom showing the SunTag-based recruitment system of SSAP RecT and Cas12a protein. The 10X GCN4 peptide was fused expression with Cas12a through a nucleoplasmin NLS-GS peptide linker, and BFP was spliced expression by T2A peptide. The RecT was fused expression with scFV through a SV40 NLS-GS peptide linker. <bold>(B)</bold> Schematic showing the 2A-mKate template design and genomic knock-in assay of HDR editing. <bold>(C)</bold> Comparison of HDR efficiencies using different SSAPs and Cas12a homologs on <italic>DYNLT1</italic> and <italic>AAVS1</italic> sites. NR, Cas12a control without RecT (No-RecT, NR) to measure the baseline level of editing. All results here and later are from replicate experiments (<italic>n</italic> &#x3d; 3), with error bars representing standard error of the mean (S.E.M.), unless otherwise noted. &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001 verus NR group. ns, no significant verus NR group. <bold>(D)</bold> Comparison of HDR efficiencies using different template designs on <italic>DYNLT1</italic> and <italic>AAVS1</italic> sites. &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001 verus NR group; &#x23;&#x23;<italic>p</italic> &#x3c; 0.01, &#x23;&#x23;&#x23;<italic>p</italic> &#x3c; 0.001 verus 100 &#x2b; 100bp group. <bold>(E)</bold> Validation of Cas12a-REDIT across different human cell types in HeLa and HepG2 cell lines. &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001 verus NR group. SSAP, single-stranded annealing protein; NLS, nuclear localization signal; GS, glycine-serine linker; BFP, blue fluorescent protein; HDR, homology-directed repair.</p>
</caption>
<graphic xlink:href="fcell-09-719705-g001.tif"/>
</fig>
<p>We tested our system <italic>via</italic> a genomic knock-in assay where a repair template of a T2A-mKate cassette (&#x223c;1&#xa0;kb in length) was provided. The template bears homology arms (HA) on both sides that match the last exon (in-frame before the stop codon) of the target genes (<xref ref-type="fig" rid="F1">Figure 1B</xref>). HDR efficiency was then quantified by fluorescence-activated cell sorting (FACS) where the percentage of mKate-positive cells represents successful knock-in.</p>
<p>Many types of Cas12a orthologs have been found across different bacteria; among those, <italic>Acidaminococcus sp.</italic> Cas12a (AsCas12a) and <italic>L. bacterium</italic> Cas12a (LbCas12a) are the two that are most efficient and commonly used (<xref ref-type="bibr" rid="B24">Zetsche et al., 2015</xref>). Therefore, we tested our design using these two orthologs in the HEK293T cell line. As expected, across two different gene targets (<italic>DYNLT1</italic> and <italic>AASV1</italic>), there were significant increases of HDR efficiency when RecT was recruited compared to the control in both of the Cas12a variants. Moreover, AsCas12a performed slightly better compared to LbCas12a. Hence, we further optimized our design using AsCas12a in the rest of study (<xref ref-type="fig" rid="F1">Figure 1C</xref>).</p>
<p>As we have previously shown that the template HA length is a deciding factor of the HDR efficiency (<xref ref-type="bibr" rid="B21">Wang et al., 2021</xref>), we investigated such influence in Cas12a-REDIT by testing different HA designs. We found that symmetric HA performed better than asymmetric HA in general, and while our design could work with as short as &#x223c;100&#xa0;bp template HA on each side, the efficiency increased as the HA length increased. A template that had &#x223c;400&#xa0;bp HA on both sides performed the best among all six designs tested (<xref ref-type="fig" rid="F1">Figure 1D</xref>).</p>
<p>Next, we examined our designs in two more different human cell lines, Hela (cervix-derived) and HepG2 (liver-derived), in order to evaluate the generalizability of our system. As expected, there were notable improvements of nearly 2-fold in the HDR efficiency (<xref ref-type="fig" rid="F1">Figure 1E</xref>).</p>
<p>To investigate whether the improvement persisted in the case of multi-target editing, two genes <italic>DYNLT1</italic> and <italic>EMX1</italic> were targeted at the same time where mKate was inserted into <italic>DYNLT1</italic> and a 16bp insertion was made into <italic>EMX1</italic>. For the latter, next-generation sequencing was performed to assay the editing efficiency. There was a nearly four-fold increase of editing efficiency for both long and short knock-in editing when using the Cas12a REDIT method (<xref ref-type="fig" rid="F2">Figure 2A</xref>). This enhancement of editing efficiencies in multiple-target settings were further validated by changing <italic>DYNLT1</italic> locus to <italic>AAVS1</italic> (<xref ref-type="fig" rid="F2">Figure 2B</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Cas12a-REDIT improves multiplexed genome editing efficiency without compromising the specificity of Cas12a. <bold>(A</bold>,<bold>B)</bold> HDR efficiencies of Cas12a and Cas12a-REDIT in the case of simultaneously targeting <bold>(A)</bold> <italic>DYNLT1</italic> and <italic>EMX1</italic> sites and <bold>(B)</bold> <italic>AAVS1</italic> and <italic>EMX1</italic> sites. Top schematic shows the vector design; mKate is inserted to <italic>DYNLT1</italic>/<italic>AAVS1</italic> locus and a 16&#xa0;bp restriction site is inserted to EMX1 locus. &#x2a;<italic>p</italic> &#x3c; 0.1, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01 versus NR group. <bold>(C)</bold> Schematic on the top showing vector designs of 4-guide RNA arrays with four guides in different order. mKate is inserted into <italic>DYNLT1</italic> site and GFP is inserted into <italic>AAVS1</italic> site, and HDR efficiencies of successful knock-in on both sites are shown on the bottom. &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001 versus NR group. <bold>(D</bold>,<bold>E)</bold> High-throughput NGS measurement of on/off-target editing events on known off-target sites of <italic>EMX1</italic> and <italic>VEGFA</italic> locus. ns, no-significant versus NR group.</p>
</caption>
<graphic xlink:href="fcell-09-719705-g002.tif"/>
</fig>
<p>Multiple genes can be edited by expressing a single CRISPR-Cas12a crRNA array together with Cas12a protein, taking advantage of its dual DNase and RNase activity (<xref ref-type="bibr" rid="B25">Zetsche et al., 2017</xref>). To further understand the potential of multiple-target editing using this system, we then targeted four genes (<italic>AAVS1</italic>, <italic>DYNLT1</italic>, <italic>EMX1</italic>, <italic>DNMT1</italic>) using a crRNA array and inserted mKate into <italic>DYNLT1</italic> locus and GFP into <italic>AAVS1</italic> locus at the same time. Focusing on fluorescent tag knock-in editing, we tested four different array designs with four guides in distinct orders, and achieved successful simultaneous HDR editing of both mKate and GFP with an approximate 2&#x2013;4.5-fold increase in efficiency using Cas12a-REDIT (<xref ref-type="fig" rid="F2">Figure 2C</xref>). While we maintained the guide sequence across the designs, we observed different editing efficiencies (<xref ref-type="fig" rid="F2">Figure 2C</xref>). This is likely due to the varying processing efficiencies of crRNA array by Cas12a protein. This processing could be influenced by multiple factors. On one hand, the positioning of the crRNA within an array could influence the processing efficiencies, thus leading to variable expression levels of individual guide depending on the position, explaining the results we observed (<xref ref-type="bibr" rid="B2">Campa et al., 2019</xref>). On the other hand, recent work (<xref ref-type="bibr" rid="B15">Magnusson et al., 2021</xref>) also reported that the guide sequence could also influence the processing efficiencies of Cas12a crRNA arrays, which could also contribute to the differences in editing outcomes when we change the position of crRNAs within an array.</p>
<p>After validating the multi-target editing of the Cas12a-REDIT method, we additionally assayed the off-target effect of our design by profiling the editing events on potential off-target sites (OTS). We examined two genes, <italic>EMX1</italic> and <italic>VEGFA</italic>, and OTS were predicted using <ext-link ext-link-type="uri" xlink:href="http://crispor.org">http://crispor.org</ext-link>. Based on the score ranking, five <italic>EMX1</italic> OTS and six <italic>VEGFA</italic> OTS were selected (sequences listed in <xref ref-type="sec" rid="s9">Supplementary Table</xref>), and editing efficiencies on these OTS were determined by next-generation sequencing. For both <italic>EMX1</italic> and <italic>VEGFA</italic>, our system exhibited no markable increase in the off-target editing (<xref ref-type="fig" rid="F2">Figures 2D,E</xref>).</p>
<p>In summary, by employing the SSAP activity of phage RecT, we engineered a Cas12a-based system that can increase the efficiency of kilo-base scale HDR editing without compromising its specificity, and such improvements could also be achieved in multiplex genome editing.</p>
<p>In the longer term, additional method development could enhance the utility of this multiplex genome knock-in system. Specifically, many emerging areas of gene-editing research will have significant synergy with our work: protein engineering to define minimal-functional Cas12a-RecT editor including to optimize its efficiency; more powerful delivery systems including for the repair templates, which is very challenging for <italic>in vivo</italic> application of this multiplex editor. These additional advancements will further enhance our approach and help to achieve high-efficiency, multi-target long-sequence editing in human cells.</p>
</sec>
</body>
<back>
<sec id="s4">
<title>Data Availability Statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: NCBI BioProject PRJNA735023.</p>
</sec>
<sec id="s5">
<title>Author Contributions</title>
<p>LC conceived of the project. CW, QX, and QZ performed genome engineering experiments. QX, CW, JC, and LC performed the off-target sequencing. CW and QX performed deep amplicon sequencing experiments. JC, CW, and LC performed computational analysis of sequencing data. LC supervised the research and experimental design. QZ, CW, and LC wrote the manuscript with input from all authors.</p>
</sec>
<sec id="s6">
<title>Funding</title>
<p>This work was supported by the National Institutes of Health (1R35HG011316 to LC); a Donald and Delia Baxter Foundation Faculty Scholar award (LC). The computational work is supported by NIH grant 1S10OD023452 to Stanford Genomics Cluster (SCG). We thank the entire Le Cong and Michael Cleary laboratory for their support, and for comments on the manuscript. We thank Feng Pan, Xin Yang, Li Zhu for generous help.</p>
</sec>
<sec sec-type="COI-statement" id="s7">
<title>Conflict of Interest</title>
<p>Stanford University has filed patent applications based on this work. The authors will make the reagents openly available to the academic community through Addgene.</p>
</sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s9">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcell.2021.719705/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcell.2021.719705/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet1.docx" id="SM2" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anzalone</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Koblan</surname>
<given-names>L. W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D. R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Genome Editing with CRISPR-Cas Nucleases, Base Editors, Transposases and Prime Editors</article-title>. <source>Nat. Biotechnol.</source> <volume>38</volume>, <fpage>824</fpage>&#x2013;<lpage>844</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-020-0561-9</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campa</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Weisbach</surname>
<given-names>N. R.</given-names>
</name>
<name>
<surname>Santinha</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Incarnato</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Platt</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Multiplexed Genome Engineering by Cas12a and CRISPR Arrays Encoded on Single Transcripts</article-title>. <source>Nat. Methods</source> <volume>16</volume>, <fpage>887</fpage>&#x2013;<lpage>893</lpage>. <pub-id pub-id-type="doi">10.1038/s41592-019-0508-6</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clement</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Canver</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Gehrke</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Farouni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>J. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>CRISPResso2 Provides Accurate and Rapid Genome Editing Sequence Analysis</article-title>. <source>Nat. Biotechnol.</source> <volume>37</volume> (<issue>3</issue>), <fpage>224</fpage>&#x2013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-019-0032-3</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>F. A.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barretto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Habib</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Multiplex Genome Engineering Using CRISPR/Cas Systems</article-title>. <source>Science</source> <volume>339</volume>, <fpage>819</fpage>&#x2013;<lpage>823</lpage>. <pub-id pub-id-type="doi">10.1126/science.1231143</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Lander</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Development and Applications of CRISPR-Cas9 for Genome Engineering</article-title>. <source>Cell</source> <volume>157</volume>, <fpage>1262</fpage>&#x2013;<lpage>1278</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.05.010</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Brunetti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gundry</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>DNA Epigenome Editing Using CRISPR-Cas SunTag-Directed DNMT3A</article-title>. <source>Genome Biol.</source> <volume>18</volume>, <fpage>176</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-017-1306-z</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jinek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>East</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Doudna</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>RNA-Programmed Genome Editing in Human Cells</article-title>. <source>eLife</source> <volume>2</volume>, <fpage>e00471</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.00471</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hur</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Been</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>S.-h.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.-S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Genome-Wide Analysis Reveals Specificities of Cpf1 Endonucleases in Human Cells</article-title>. <source>Nat. Biotechnol.</source> <volume>34</volume> (<issue>8</issue>), <fpage>863</fpage>&#x2013;<lpage>868</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3609</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kleinstiver</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Sousa</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>R. T.</given-names>
</name>
<name>
<surname>Tak</surname>
<given-names>Y. E.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Clement</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Engineered CRISPR-Cas12a Variants with Increased Activities and Improved Targeting Ranges for Gene, Epigenetic and Base Editing</article-title>. <source>Nat. Biotechnol.</source> <volume>37</volume>, <fpage>276</fpage>&#x2013;<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-018-0011-0</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kleinstiver</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>S. Q.</given-names>
</name>
<name>
<surname>Prew</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>N. T.</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Genome-Wide Specificities of CRISPR-Cas Cpf1 Nucleases in Human Cells</article-title>. <source>Nat. Biotechnol.</source> <volume>34</volume> (<issue>8</issue>), <fpage>869</fpage>&#x2013;<lpage>874</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3620</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knott</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Doudna</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>CRISPR-Cas Guides the Future of Genetic Engineering</article-title>. <source>Science</source> <volume>361</volume>, <fpage>866</fpage>&#x2013;<lpage>869</lpage>. <pub-id pub-id-type="doi">10.1126/science.aat5011</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komor</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Badran</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D. R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes</article-title>. <source>Cell</source> <volume>168</volume>, <fpage>20</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.10.044</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>CRISPR-Cpf1-Mediated Genome Editing and Gene Regulation in Human Cells</article-title>. <source>Biotechnol. Adv.</source> <volume>37</volume> (<issue>1</issue>), <fpage>21</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.biotechadv.2018.10.013</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Base Editing with a Cpf1-Cytidine Deaminase Fusion</article-title>. <source>Nat. Biotechnol.</source> <volume>36</volume>, <fpage>324</fpage>&#x2013;<lpage>327</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.4102</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magnusson</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Rios</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>L. S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Enhanced Cas12a Multi-Gene Regulation Using a CRISPR Array Separator</article-title>. <source>Elife</source> <volume>9</volume> (<issue>10</issue>), <fpage>e66406</fpage>. <pub-id pub-id-type="doi">10.7554/elife.66406</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCarty</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Studen&#xe1;</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ledesma-Amaro</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Multiplexed CRISPR Technologies for Gene Editing and Transcriptional Regulation</article-title>. <source>Nat. Commun.</source> <volume>11</volume>, <fpage>1281</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-15053-x</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pickar-Oliver</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gersbach</surname>
<given-names>C. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The Next Generation of CRISPR-Cas Technologies and Applications</article-title>. <source>Nat. Rev. Mol. Cel. Biol.</source> <volume>20</volume>, <fpage>490</fpage>&#x2013;<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-019-0131-5</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swarts</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>van der Oost</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jinek</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Structural Basis for Guide RNA Processing and Seed-Dependent DNA Targeting by CRISPR-Cas12a</article-title>. <source>Mol. Cel.</source> <volume>66</volume> (<issue>2</issue>), <fpage>221</fpage>&#x2013;<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2017.03.016</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tak</surname>
<given-names>Y. E.</given-names>
</name>
<name>
<surname>Kleinstiver</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Nu&#xf1;ez</surname>
<given-names>J. K.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Horng</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Inducible and Multiplex Gene Regulation Using CRISPR-Cpf1-Based Transcription Factors</article-title>. <source>Nat. Methods</source> <volume>14</volume>, <fpage>1163</fpage>&#x2013;<lpage>1166</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.4483</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanenbaum</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Weissman</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Vale</surname>
<given-names>R. D.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging</article-title>. <source>Cell</source> <volume>159</volume>, <fpage>635</fpage>&#x2013;<lpage>646</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.09.039</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J. K. W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>N. W.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Winslow</surname>
<given-names>M. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Microbial Single-Strand Annealing Proteins Enable CRISPR Gene-Editing Tools with Improved Knock-In Efficiencies and Reduced Off-Target Effects</article-title>. <source>Nucleic Acids Res.</source> <volume>49</volume>, <fpage>e36</fpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa1264</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Cas12a Base Editors Induce Efficient and Specific Editing with Low DNA Damage Response</article-title>. <source>Cel. Rep.</source> <volume>31</volume> (<issue>9</issue>), <fpage>107723</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2020.107723</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nishimasu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zetsche</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hirano</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Slaymaker</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Crystal Structure of Cpf1 in Complex with Guide RNA and Target DNA</article-title>. <source>Cell</source> <volume>165</volume>, <fpage>949</fpage>&#x2013;<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.04.003</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zetsche</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gootenberg</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Abudayyeh</surname>
<given-names>O. O.</given-names>
</name>
<name>
<surname>Slaymaker</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>Makarova</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Essletzbichler</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System</article-title>. <source>Cell</source> <volume>163</volume>, <fpage>759</fpage>&#x2013;<lpage>771</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.09.038</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zetsche</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Heidenreich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mohanraju</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fedorova</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kneppers</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>DeGennaro</surname>
<given-names>E. M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Multiplex Gene Editing by CRISPR-Cpf1 Using a Single crRNA Array</article-title>. <source>Nat. Biotechnol.</source> <volume>35</volume> (<issue>1</issue>), <fpage>31</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3737</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>